HS-130: The First Allogeneic, Off-the-Shelf Cell Therapy that Delivers Localized OX40-mediated Co-Stimulation to Enhance T-cell Activation in Lung Cancer (NSCLC)
HS-130 is designed to enhance the gp96 platform by facilitating antigen-driven T-cell activation and OX40L co-stimulation in a single product. The T-cell co-stimulatory fusion protein OX40L-Ig has the potential to combine with other immunotherapies, including HS-110, to potentially enhance the activation of antigen-specific CD8+ T-cells, stimulate the generation of long-lasting T-cell memory, and support the differentiation of T follicular helper cells that facilitate antibody production by B cells.